PMID

Data

Article Title

Organization

Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.

Rallis India

Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.

East China University Of Science & Technology

Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.

Oribase Pharma

Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.

Experimental Therapeutics Centre

Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.

First Affiliated Hospital Of Xi'An Jiaotong University

Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib.

Xi'An Jiaotong University

Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents.

Xi'An Jiaotong University

Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.

Guangzhou Institutes Of Biomedicine And Health

Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level.

The University Of Texas M.D. Anderson Cancer Center

The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.

Novartis Institutes For Biomedical Research

Design, synthesis and biological activities of Nilotinib derivates as antitumor agents.

Xi'An Jiaotong University

BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.

The First People'S Hospital Of Hangzhou

Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.

University Of Nottingham

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)¿isoleucine(315) mutant.

Chinese Academy Of Sciences

Features of selective kinase inhibitors.

University Of California San Francisco

Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

University Of South Florida

3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.

Chiron

Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.

Universit£

Hybrid compounds as new Bcr/Abl inhibitors.

Chinese Academy Of Sciences

Expanding the diversity of allosteric bcr-abl inhibitors.

Harvard Medical School

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.

Novartis Institutes For Biomedical Research

Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase.

Temple University School Of Medicine

Allosteric inhibitors of Bcr-abl-dependent cell proliferation.

Genomics Institute Of The Novartis Research Foundation

Selectively nonselective kinase inhibition: striking the right balance.

Schering-Plough

Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.

University Of Milano-Bicocca

Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.

University Of Regensburg

Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase.

Chembridge Research Laboratories And Chembridge

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Bristol-Myers Squibb Pharmaceutical Research Institute

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.

Novartis Institutes For Biomedical Research